Certain patients with IBD are more likely to see poor outcomes due to low socioeconomic status (SES). Recognizing and acting on these differences is especially important during the COVID-19 pandemic, the economic consequences of which have disproportionately affected those with low SES.
In the second episode of this CMEOCast podcast series, expert faculty focus on the role of SES and gender bias in the treatment of IBD and offer approaches to mitigating these disparities.
At the end of this CME/CE activity, participants should be able to initiate multidisciplinary collaboration to provide medically underserved children, adolescents, and adults with IBD with guideline-recommended care.
Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc.
Physicians, nurse practitioners, PAs, nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on the advisory boards or a consultant for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
Dr. Quezada has no disclosures to report.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Michael J. Franks, MSN, AGACNP-BC, FNP-BC (peer reviewer) has no disclosures to report.
Olga Askinazi, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-033-H01-P
Call us at (877) CME-PROS or (877) 263-7767.